Anticancer agent 355
Anticancer agent 355 is a highly selective and potent anticancer agent, with IC50 values of 64.66 μM and 13.35 μM against HeLa and MDA-MB-231 cancer cells, respectively. Anticancer agent 355 induces plasmid DNA degradation via intercalation or minor groove binding, and disrupts the tertiary structure of BSA by interfering with the interactions of amino acid side chains. Anticancer agent 355 can be used in the research of cervical cancer and breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 78831-35-3
- Fòrmula: C16H12N2O4
- Peso molecular:296.28
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
64.66 μM
|
Cytotoxicity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
j.inoche.2020.108085 |
| MDA-MB-231 | IC50 |
13.35 μM
|
Cytotoxicity against human breast cancer MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against human breast cancer MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
j.inoche.2020.108085 |
| HEK293 | IC50 |
82.75 μM
|
Cytotoxicity against normal human fibroblast HEK-293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against normal human fibroblast HEK-293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
j.inoche.2020.108085 |
Anticancer agent 355 (Compound S4) (1-3 mg/mL; 1 h) completely degrades plasmid DNA of approximately 1 kb, exhibiting strong chemical nuclease activity[1].
Anticancer agent 355 (9-300 μM; 24 h) exhibits cytotoxicity against HeLa and MDA-MB-231 cancer cells, with IC50 values of 64.66 μM and 13.35 μM, respectively. Meanwhile, compared to normal HEK-293 cells (IC50 = 82.75 μM), this agent shows high selectivity for MDA-MB-231 cells, with a selectivity coefficient of 6.19[1].
Anticancer agent 355 (30 µM) exhibits potent DNA-binding activity via an intercalation mode in in vitro biochemical reactions[1].
Anticancer agent 355 binds to BSA in in vitro biochemical reactions, inducing fluorescence quenching and disruption of the protein's tertiary structure[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 78831-35-3
-
Peso molecular 296.28
-
Fòrmula C16H12N2O4
-
SMILES
O=C(C1=NC2=C3N=C(C(OC)=O)C=CC3=CC=C2C=C1)OC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 355 Related Classifications
HY-187163 Related Classifications
Powered by Bioz